COMPANY RESEARCHDaiichi Sankyo Company, Limited
Daiichi Sankyo is a Japanese global pharmaceutical company researching, developing and commercializing prescription medicines. Its R&D activities include small molecules, biologic approaches and antibody-drug conjugate technologies, with significant work in oncology and selected cardiovascular and specialty diseases. The company maintains research and commercial operations internationally and collaborates with other drug developers. Headquartered in Tokyo, Daiichi Sankyo is listed on the Tokyo Stock Exchange under securities code 4568. This profile is intended as a stable directory description, not as an exhaustive catalog of products, treatment indications or clinical phases.
Company at a glance
Corporate information
- Company entity
- Daiichi Sankyo
- Headquarters / principal office
- Chuo-ku, TokyoSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2005
Sources (1)
- Daiichi Sankyo HistoryNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- DAICHIRONA Japan approval announcement2023-11-28
- Official corporate reference
- https://www.daiichisankyo.com/
Sources (1)
- DAICHIRONA Japan approval announcement2023-11-28
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Daiichi Sankyo · LinkedIn Company Page主页Not stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Daiichi Sankyo is a Japanese global pharmaceutical company researching, developing and commercializing prescription medicines. Its R&D activities include small molecules, biologic approaches and antibody-drug conjugate technologies, with significant work in oncology and selected cardiovascular and specialty diseases. The company maintains research and commercial operations internationally and collaborates with other drug developers. Headquartered in Tokyo, Daiichi Sankyo is listed on the Tokyo Stock Exchange under securities code 4568. This profile is intended as a stable directory description, not as an exhaustive catalog of products, treatment indications or clinical phases.
TSE: 4568
antibody-drug conjugates · small molecules · biologics
oncology · cardiovascular diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
In 2023 Daiichi Sankyo announced Japanese approval of its DAICHIRONA (DS-5670) mRNA COVID-19 vaccine. The approved product should be evaluated separately from other newer programs.
Business, technology & evidence
- The PMDA review report index lists initial approval of DAICHIRONA in August 2023, followed by supplemental approvals.
- Daiichi Sankyo is a Japanese global pharmaceutical company researching, developing and commercializing prescription medicines. Its R&D activities include small molecules, biologic approaches and antibody-drug conjugate technologies, with significant work in oncology and selected cardiovascular and specialty diseases. The company maintains research and commercial operations internationally and collaborates with other drug developers. Headquartered in Tokyo, Daiichi Sankyo is listed on the Tokyo Stock Exchange under securities code 4568. This profile is intended as a stable directory description, not as an exhaustive catalog of products, treatment indications or clinical phases.
- SecuritiesTSE: 4568
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| DAICHIRONA / DS-5670 | SARS-CoV-2 antigen · COVID-19 prevention | Approved (DAICHIRONA; company announcement) | Refer to the program-specific stage source. This record does not include unverified cross-trial results or efficacy rankings. |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- The pipeline is not exhaustive. Evidence for a representative program should not be attributed to the entire platform.
- DAICHIRONA Japan approval announcement ↗Daiichi Sankyo · 2023-11-28
- PMDA Review Reports: Daichirona ↗PMDA · 2023 / 2025
- Official issuer and R&D disclosure · Daiichi Sankyo Company, Limited ↗Daiichi Sankyo Company, Limited ·
- Daiichi Sankyo · LinkedIn Company Page主页 ↗Daiichi Sankyo / LinkedIn · Not stated
- Daiichi Sankyo History ↗Daiichi Sankyo · Not stated
- Official corporate website audit ↗Daiichi Sankyo · 2026-11-04 retrieval; original page date where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.